(603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
Filed with SSE · Stock code 603998 · · 2 pages · Chinese
Summary by 6ix AI
The meeting confirmed the approval of a proposal regarding the management measures for the incentive fund.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Hunan Fangsheng Pharmaceutical Co., Ltd. on 6ix
Story so far
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Notice on Convening the 2nd Extraordinary General Meeting in 2026
- Announcement on Resolutions of the 6th Extraordinary Meeting of the 6th Board of Directors in 2026
- Announcement on Progress of Transfer of Certain Equity Interests in a Controlled Subsidiary and Introduction of Strategic Investors
Earlier from Hunan Fangsheng Pharmaceutical
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Notice on Convening the 2nd Extraordinary General Meeting in 2026
- Announcement on Resolutions of the 6th Extraordinary Meeting of the 6th Board of Directors in 2026
- Announcement on Progress of Transfer of Certain Equity Interests in a Controlled Subsidiary and Introduction of Strategic Investors
- Announcement on Implementation of Dividend Distribution for the First Half of 2026
- Announcement on Outline of the 2026 Semi-annual Performance and Cash Dividend Briefing
Later from Hunan Fangsheng Pharmaceutical
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Receipt of Drug Registration Certificate for Cobamamide Capsules
- (603998)"HUNAN FANGSHENG PHARMACEUTICAL CO., LTD."Announcement on Convening the Q3 2026 Performance Briefing
Follow Hunan Fangsheng Pharmaceutical into a list and get an email when it puts out news.
Follow Hunan Fangsheng Pharmaceutical